WAM
DMAAR

Warberg Asset Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Warberg Asset Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,443
Closed -$2.4K – 236
2025
Q1 		$2.4K Buy
+18,443
New +$2.59K ﹤0.01% 175

Other funds holding DMAAR

Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
HCI
Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $567M AUM 0.34% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Warberg Asset Management's DMAAR Position: Q2 2025 in Review

Warberg Asset Management sold out of Drugs Made In America Acquisition Corp Rights (DMAAR) in Q2 2025, closing a stake of 18,443 shares — an estimated $2.4K sold.

Warberg Asset Management first reported a position in DMAAR in Q1 2025 and held it in 1 quarter. The position peaked at $2.4K in Q1 2025. 24 funds tracked by Wall St. Rank hold DMAAR as of Q2 2025.

  • Warberg Asset Management reported no remaining Drugs Made In America Acquisition Corp Rights position as of Q2 2025 after selling out during the quarter.
  • Warberg Asset Management sold 18,443 Drugs Made In America Acquisition Corp Rights shares in Q2 2025, an estimated $2.4K.
  • Warberg Asset Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and held it in 1 quarter.
  • Warberg Asset Management's Drugs Made In America Acquisition Corp Rights position peaked at $2.4K in Q1 2025.
  • 24 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2025.

Based on Warberg Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.